AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06427239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab will be administrated per dose level in which the patients are assigned
Study NCT04419779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing (DMR)
Description: The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
Study NCT04419779 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing (Sham)
Description: The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
Study NCT06149117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®
Description: Take one capsule orally every cycle(T or R)
Study NCT05819073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain water
Description: Subjects will use plain water as an oral rinse twice a day for 3 days.
Study NCT05819073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPE
Description: Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
Study NCT04888052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute ACL injury
Description: Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits > 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
Study NCT04609787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
Study NCT05248841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC-Glargine
Description: Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
Study NCT05248841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Lantus
Description: Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
Study NCT04526717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MPT0B640
Description: Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
Study NCT05466500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided axillary block with intravenous dexamethasone
Description: it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
Study NCT05466500 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided axillary block
Description: it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
Study NCT06191991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg
Study NCT06191991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: 0.9 mg
Study NCT06191991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg
Study NCT05600556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05600556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05600556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Review imaging on standard computer screen
Study NCT05600556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT05600556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05600556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05600556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Technology Intervention
Description: Review virtual reality images
Study NCT05600556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT06550284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The intervention will be physical therapy standard care.
Study NCT04880603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restrata Graft
Description: Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.
Study NCT04880603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Skin Graft
Description: Standard of Care Skin Graft
Study NCT05222698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Facial reanimation surgery by free muscle trasfer.
Description: Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
Study NCT05321732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 A mg
Study NCT05321732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP202010
Description: DWP202010 B mg
Study NCT05414344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Brief Intervention
Description: Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
Study NCT05414344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed and Peer-Supported Brief Intervention
Description: In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
Study NCT04584346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquigen MCT oil
Description: MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
Study NCT04584346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard American Diet
Description: Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
Study NCT05414344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment only
Description: Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
Study NCT05349552 — intervention group
Intervention type: RADIATION
Intervention: stereotactic body radiation therapy
Description: The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
Study NCT05137457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivering Online ZZZ's with Empirical support (DOZE) app
Description: The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal.
Study NCT05137457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep diary
Description: The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
Study NCT05137457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep diary
Description: The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
Study NCT05045742 — intervention group
Intervention type: OTHER
Intervention: Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2
Description: We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
Study NCT06053073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical rippening at home
Description: The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
Study NCT06053073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical rippening in the hospital
Description: The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
Study NCT06432374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WET
Description: The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions.
Study NCT05332873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivet Shunt
Description: The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
Study NCT06216704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance relaxometry
Description: Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
Study NCT06416956 — intervention group
Intervention type: DRUG
Intervention: Caffeine
Description: We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
Study NCT06551415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate 150mg
Description: 100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
Study NCT06551415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5MG
Description: 100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
Study NCT05738278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HR-informed change in routine
Description: The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure.
Study NCT05738278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed HR-informed specific change in routine
Description: The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure.
Study NCT06469203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
Study NCT06469203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9% Inj
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
Study NCT06469203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
Study NCT06440993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1,000 mg/m2 IV
Study NCT06440993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 25 mg/m2 IV
Study NCT06440993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab, 1,500 mg IV
Study NCT06440993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ID-RFA
Description: endoscopic intraductal RFA
Study NCT06216704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance spectroscopy
Description: Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
Study NCT06216704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
Study NCT06216704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DXA
Description: DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
Study NCT05544942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: 1 capsule once a day
Study NCT05544942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: 1 capsule once a day
Study NCT05139199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure group
Description: A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
Study NCT05268393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BREATHE-T1D
Description: BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.
Study NCT05268393 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BREATHE-T1D
Description: BREATHE-T1D is a mindfulness based intervention adapted from Learning to BREATHE specifically for teens with type 1 diabetes.